As partners Arena Pharmaceuticals Inc. and Eisai Inc. prepare for a new FDA advisory committee review on May 10 for the weight loss drug lorcaserin, they have the benefit of greater clarity on regulatory policy based on encouraging recent developments for two competing candidates.
The Endocrinologic and Metabolic Drugs Advisory Committee will be considering the resubmission of the candidate after a “complete response” letter...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?